Promising Therapeutic Targets in Kidney Renal Clear Cell Carcinoma: PLXNA1 and PLXNB3.

IF 2.4 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Cancer Biotherapy and Radiopharmaceuticals Pub Date : 2024-05-01 Epub Date: 2021-12-01 DOI:10.1089/cbr.2021.0336
Can-Xuan Li, Dan Long, Quan Meng
{"title":"Promising Therapeutic Targets in Kidney Renal Clear Cell Carcinoma: <i>PLXNA1</i> and <i>PLXNB3</i>.","authors":"Can-Xuan Li, Dan Long, Quan Meng","doi":"10.1089/cbr.2021.0336","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Aims:</i></b> This study sets out to identify dysregulated plexins and investigate their roles in KIRC through an integrated bioinformatics approach. <b><i>Methods:</i></b> RNA-sequencing data and clinicopathological information of KIRC, extracted from The Cancer Genome Atlas (TCGA) database, were used to perform comprehensive bioinformatics analysis. <b><i>Results:</i></b> Almost all plexin gene family members were dysregulated in KIRC. Univariate and multivariate Cox regression analyses revealed that <i>PLXNA1/B3</i> were independent prognostic factors of overall survival in patients with KIRC. Mechanically, <i>PLXNA1/B3</i> may promote ccRCC progression through several cancer-related signaling pathways, tumor immunity, and angiogenesis. Drug sensitivity analysis suggested that vemurafenib was the potential drug for <i>PLXNA1/B3</i>. <b><i>Conclusion:</i></b> Herein, we found that <i>PLXNA1/B3</i> were independent prognostic factors, making them attractive new targets for KIRC treatment.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"276-290"},"PeriodicalIF":2.4000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biotherapy and Radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/cbr.2021.0336","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/12/1 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: This study sets out to identify dysregulated plexins and investigate their roles in KIRC through an integrated bioinformatics approach. Methods: RNA-sequencing data and clinicopathological information of KIRC, extracted from The Cancer Genome Atlas (TCGA) database, were used to perform comprehensive bioinformatics analysis. Results: Almost all plexin gene family members were dysregulated in KIRC. Univariate and multivariate Cox regression analyses revealed that PLXNA1/B3 were independent prognostic factors of overall survival in patients with KIRC. Mechanically, PLXNA1/B3 may promote ccRCC progression through several cancer-related signaling pathways, tumor immunity, and angiogenesis. Drug sensitivity analysis suggested that vemurafenib was the potential drug for PLXNA1/B3. Conclusion: Herein, we found that PLXNA1/B3 were independent prognostic factors, making them attractive new targets for KIRC treatment.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肾脏透明细胞癌的有望治疗靶点:PLXNA1 和 PLXNB3。
目的:本研究旨在通过综合生物信息学方法,识别调控失调的 plexins 并研究它们在 KIRC 中的作用。研究方法从癌症基因组图谱(TCGA)数据库中提取 KIRC 的 RNA 序列数据和临床病理信息,进行综合生物信息学分析。结果KIRC中几乎所有的plexin基因家族成员都出现了调控异常。单变量和多变量Cox回归分析显示,PLXNA1/B3是影响KIRC患者总生存期的独立预后因素。从机理上讲,PLXNA1/B3可能会通过几种癌症相关的信号通路、肿瘤免疫和血管生成来促进ccRCC的进展。药物敏感性分析表明,vemurafenib是治疗PLXNA1/B3的潜在药物。结论在本文中,我们发现 PLXNA1/B3 是独立的预后因素,使其成为治疗 KIRC 的有吸引力的新靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.80
自引率
2.90%
发文量
87
审稿时长
3 months
期刊介绍: Cancer Biotherapy and Radiopharmaceuticals is the established peer-reviewed journal, with over 25 years of cutting-edge content on innovative therapeutic investigations to ultimately improve cancer management. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies. The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments.
期刊最新文献
Is There Novel 18F-FDG Biodistribution in the Digital PET/CT Era? A Real-World Data Analysis. IL-21 and IL-33 May Be Effective Biomarkers to Predict the Efficacy of PD-1 Monoclonal Antibody for Advanced Cholangiocarcinoma. Exploring the Role of [68Ga]Ga-DOTAGA-IAC and Comparison of Its Diagnostic Performance with [18F]F-FDG PET/CT in Radioiodine Refractory Differentiated Thyroid Carcinoma. Generalized Seizure as an Acute post-Lu177-DOTATATE Side Effect in a Case of Recurrent Meningioma. Identification of a Vascular Endothelial Growth Factor Receptor-3 Binding Peptide TMVP1 for Enhancing Drug Delivery Efficiency and Therapeutic Efficacy Against Tumor Lymphangiogenesis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1